The Stock2Me Podcast

Stock2Me's latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies. Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital. “In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I'm aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.” Join IBN's Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.  

Stock2Me's latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies. Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital. “In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I'm aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.” Join IBN's Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.

Stock2Me's latest podcast features David Jemmett, CEO and Founder of Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) (“CISO Global” or the “Company”), an industry leader in cybersecurity and compliance services. Throughout the interview, Jemmett discussed the core values and mission of Cerberus Sentinel. “Cerberus Sentinel was founded at a period of time when there were 800,000 job openings in cyber. There's been a zero jobless rate since 2011. This year alone there are four million job openings [in cyber] globally,” Jemmett said. “A lot of my friends and coworkers have started cybersecurity companies in the past, but they were very verticalized – training, gap analysis, compliance or SOC services… At Cerberus Sentinel, we help our clients find their cyber issues, remediate them and keep on top of them. Cybersecurity is a journey; it's not an endpoint. We'll continue to work on the evolving threat matrix with our customers to help them keep improving.” Join IBN's Stuart Smith and David Jemmett to learn more about the company's unique offerings in the cyber space and how they differentiate Cerberus Sentinel from the competition.  

Stock2Me's latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.  In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company's recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets.  “BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries.  The latest installment of The Stock2Me Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.  To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine 

Stock2Me's latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases.  In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company's recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets.  “BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries.  The latest installment of The Stock2Me Podcast continues to reinforce IBN's commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.  To learn more about IBN's achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine 

Stock2Me's latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey's sports advisory board, which aims to support the company's efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health. “I had a unique, long career playing for the Women's National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I've been retired for six years), I've had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me's latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey's sports advisory board, which aims to support the company's efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health. “I had a unique, long career playing for the Women's National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I've been retired for six years), I've had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me's latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications.  Throughout the interview, Clifford discussed FuelPositive's rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability.  “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We're now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We're building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

Stock2Me's latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications.  Throughout the interview, Clifford discussed FuelPositive's rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability.  “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We're now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We're building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.” 

Stock2Me's latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms. To begin the interview, Bunka provided a summary of Lexaria's business model, which is focused on leveraging the company's proprietary DehydraTECH™ drug delivery technology. “[Lexaria has] developed a drug delivery technology that's quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we're so good at it, we're actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent' our technology.”

Stock2Me's latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms. To begin the interview, Bunka provided a summary of Lexaria's business model, which is focused on leveraging the company's proprietary DehydraTECH™ drug delivery technology. “[Lexaria has] developed a drug delivery technology that's quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we're so good at it, we're actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent' our technology.”

Stock2Me's latest podcast features Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements. Throughout the interview, Clifford discussed FuelPositive's innovative carbon-free ammonia technology and its potential to change the energy landscape, both across Canada and around the world. “We have purchased, back in April 2021, a cutting-edge technology that is designed to produce carbon-free ammonia, or carbon-free NH3 as it's also known, in a proprietary, environmentally sound and economically viable process,” Clifford said. “This technology… allows for the production of ammonia in a scalable and modular fashion. That means that we can set up our systems to produce carbon-free ammonia where it's needed and when it's needed, which is a very, very significant departure from the way that ammonia is produced today… Ammonia today… is one of the most carbon-intense processes on the planet. Our system is entirely carbon-free.”

Stock2Me's latest podcast features Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements. Throughout the interview, Clifford discussed FuelPositive's innovative carbon-free ammonia technology and its potential to change the energy landscape, both across Canada and around the world. “We have purchased, back in April 2021, a cutting-edge technology that is designed to produce carbon-free ammonia, or carbon-free NH3 as it's also known, in a proprietary, environmentally sound and economically viable process,” Clifford said. “This technology… allows for the production of ammonia in a scalable and modular fashion. That means that we can set up our systems to produce carbon-free ammonia where it's needed and when it's needed, which is a very, very significant departure from the way that ammonia is produced today… Ammonia today… is one of the most carbon-intense processes on the planet. Our system is entirely carbon-free.”

Stock2Me's latest podcast features Dr. Art Dawson, U.S. Business Manager of Save Foods (NASDAQ: SVFD), an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. Throughout the interview, Dawson discussed Save Foods' innovative technology and examined how its products are helping combat excessive waste in the fresh produce industry. “The most important thing to know is that Save Foods has successfully completed the development and has also begun to market natural, eco-friendly solutions for fresh produce,” Dawson said. “These solutions are used in the process of protecting fresh fruits and vegetables, and, therefore, they're an important part of the economic scheme of the fresh produce value chain. This is because the products themselves contribute to the extension of shelf life within that value chain. They are also used simultaneously to ensure food safety and to ensure compliance with the current U.S. Food Safety Modernization Act.”

Stock2Me's latest podcast features Dr. Art Dawson, U.S. Business Manager of Save Foods (NASDAQ: SVFD), an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. Throughout the interview, Dawson discussed Save Foods' innovative technology and examined how its products are helping combat excessive waste in the fresh produce industry. “The most important thing to know is that Save Foods has successfully completed the development and has also begun to market natural, eco-friendly solutions for fresh produce,” Dawson said. “These solutions are used in the process of protecting fresh fruits and vegetables, and, therefore, they're an important part of the economic scheme of the fresh produce value chain. This is because the products themselves contribute to the extension of shelf life within that value chain. They are also used simultaneously to ensure food safety and to ensure compliance with the current U.S. Food Safety Modernization Act.”

Stock2Me's latest podcast features Shan Sawant, Director of Communications for AmpliTech Group Inc. (NASDAQ: AMPG), a company engaged in the design, development and manufacture of custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. Throughout the interview, Sawant discussed AmpliTech's business model, offering an overview of the company's proven, decades-long track record of providing vital radio frequency components to an impressive list of clients. “AmpliTech provides high-quality radio frequency (RF) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.”

Stock2Me's latest podcast features Shan Sawant, Director of Communications for AmpliTech Group Inc. (NASDAQ: AMPG), a company engaged in the design, development and manufacture of custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. Throughout the interview, Sawant discussed AmpliTech's business model, offering an overview of the company's proven, decades-long track record of providing vital radio frequency components to an impressive list of clients. “AmpliTech provides high-quality radio frequency (RF) components that allow for high performance, low noise wireless connections in devices and systems,” Sawant said. “As we know, today, virtually every mobile device requires a wireless signal of some kind, and systems are beginning to need to process more data than ever before. That creates an unprecedented demand for signal bandwidth to move applications and data in a fast and highly reliable way.”

Stock2Me's latest podcast features Allan Jones, President of Emaginos Inc., which recently submitted a U.S. patent application for its EdManage analytics platform for public education. Throughout the interview, Jones discussed how the EdManage program was developed, how it works and the benefits it provides for students. “A few years ago, our Director of Education, Dr. Keith Larick, was school superintendent in Tracy, California. He gave three teachers a clean slate and one year to design the best possible school based on proven best education practices,” Jones said. “They did that, and they've created an amazing program that's been very effective for years. What we're trying to do is take their model and make it available to other schools. That's our goal – to transform schools to this very successful model used at the Tracy Learning Center.”

Stock2Me's latest podcast features Allan Jones, President of Emaginos Inc., which recently submitted a U.S. patent application for its EdManage analytics platform for public education. Throughout the interview, Jones discussed how the EdManage program was developed, how it works and the benefits it provides for students. “A few years ago, our Director of Education, Dr. Keith Larick, was school superintendent in Tracy, California. He gave three teachers a clean slate and one year to design the best possible school based on proven best education practices,” Jones said. “They did that, and they've created an amazing program that's been very effective for years. What we're trying to do is take their model and make it available to other schools. That's our goal – to transform schools to this very successful model used at the Tracy Learning Center.”

Stock2Me's latest podcast features Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing treatments, primarily psychedelics like psilocybin, for diseases with unmet medical needs. Throughout the interview, McKee discussed the company's prospective patients and targeted ailments, the need for innovation in the psychedelics space and Tryp's planned human clinical trials later this year. “We're here fundamentally to help patients. We're also very interested in bringing new therapies to these patients. All these indications that we're working in – specifically fibromyalgia, phantom limb syndrome and complex regional pain syndrome, and potentially others such as tinnitus, cluster headaches, TMJ and others – all these subcategories of chronic pain are areas where there is significant unmet medical need,” McKee said. “In other words, situations where patients aren't properly served. We know that new chemistries and new solutions need to be brought to the table. There needs to be a broader set of tools that physicians can use to treat these patients.”

Stock2Me's latest podcast features Greg McKee, Chairman and CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing treatments, primarily psychedelics like psilocybin, for diseases with unmet medical needs. Throughout the interview, McKee discussed the company's prospective patients and targeted ailments, the need for innovation in the psychedelics space and Tryp's planned human clinical trials later this year. “We're here fundamentally to help patients. We're also very interested in bringing new therapies to these patients. All these indications that we're working in – specifically fibromyalgia, phantom limb syndrome and complex regional pain syndrome, and potentially others such as tinnitus, cluster headaches, TMJ and others – all these subcategories of chronic pain are areas where there is significant unmet medical need,” McKee said. “In other words, situations where patients aren't properly served. We know that new chemistries and new solutions need to be brought to the table. There needs to be a broader set of tools that physicians can use to treat these patients.”

Stock2Me's latest podcast features Scott Shellady, a financial markets commentator who can frequently be seen on Fox Business, Bloomberg, CNN and TD Ameritrade. During the interview, Shellady provided a brief overview of his background, his outlook on the trends guiding the market in 2021 and the importance of the next 18 months as the economy continues to get up-to-speed in the wake of the global pandemic. “I've been in the financial business – commodities, equities and fixed income – for about 34 years. Over the last probably 10 or 15 years, because I wear a black and white Holstein cow jacket… I garnered a lot of attention; people wanted to talk to the big guy in the cow jacket,” Shellady said. “Slowly but surely, I became an accidental commentator. I didn't mean for it to happen. About the time I started wearing the jacket, we started to see a lot of flows into the market, especially into fixed income, bonds and interest-rate products… Being at the Chicago Board of Trade and trading on the exchange in the pits, a lot of people could see the jacket from the visitor's gallery… One thing led to another and all of a sudden you find yourself on CNBC and Fox.” 

Stock2Me's latest podcast features Brent Bedford, President, Chairman & CEO of Perpetual Industries Inc. (OTC: PRPI). During the interview, Bedford provided an introduction to Perpetual Industries' business model and how the company is working to minimize the hurdles that can stand in the way of innovation. “Perpetual Industries really came out of an idea of innovation, helping all these great minds that we have in the world coming up with all these innovative great ideas [by] acting sort of like an incubator or a conduit to allow those ideas to be developed, researched and, ultimately, commercialized,” Bedford explained.

Stock2Me's latest podcast features Brent Bedford, President, Chairman & CEO of Perpetual Industries Inc. (OTC: PRPI). During the interview, Bedford provided an introduction to Perpetual Industries' business model and how the company is working to minimize the hurdles that can stand in the way of innovation. “Perpetual Industries really came out of an idea of innovation, helping all these great minds that we have in the world coming up with all these innovative great ideas [by] acting sort of like an incubator or a conduit to allow those ideas to be developed, researched and, ultimately, commercialized,” Bedford explained.

Stock2Me's latest podcast features Brendan Cahill, President & CEO of Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2). During the interview, Cahill provided an introduction to Excellon's business model and its current portfolio of production and exploration resource projects spanning North America and Europe. “Excellon's actually been around quite a long time. It was founded in 1989 but got to Mexico in the late ‘90s and started the Platosa Mine in 2005. It's Mexico's highest-grade silver producer,” Cahill explained. “We produce silver, lead and zinc and sell it into the global market, but Excellon's always had a big focus on exploration. So, we're also expanding in Idaho on gold projects and the very fascinating Silver City Project in Saxony, Germany – an area that was mined for 800 years for high-grade silver, with mining only stopping when Germany moved off the silver standard in 1873. We're the first ones ever to use modern exploration technology on that project, and exploration starts again within the month looking for high-grade silver deposits.”

Stock2Me's latest podcast features Brendan Cahill, President & CEO of Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2). During the interview, Cahill provided an introduction to Excellon's business model and its current portfolio of production and exploration resource projects spanning North America and Europe. “Excellon's actually been around quite a long time. It was founded in 1989 but got to Mexico in the late ‘90s and started the Platosa Mine in 2005. It's Mexico's highest-grade silver producer,” Cahill explained. “We produce silver, lead and zinc and sell it into the global market, but Excellon's always had a big focus on exploration. So, we're also expanding in Idaho on gold projects and the very fascinating Silver City Project in Saxony, Germany – an area that was mined for 800 years for high-grade silver, with mining only stopping when Germany moved off the silver standard in 1873. We're the first ones ever to use modern exploration technology on that project, and exploration starts again within the month looking for high-grade silver deposits.”

Stock2Me's latest podcast features Allan Jones, President of Emaginos Inc. During the interview, Jones discussed the company's business model and its vision of leveraging proven best practices to transform public school students from passive listeners into active learners. “We're a company that's dedicated to transforming public education. We have this vision of unleashing America's greatest natural resource – the minds of our children,” Jones said. “A teachable moment occurs when the student wants to learn what the teacher wants to teach. Good teachers can recognize those and take advantage of them; great teachers can create them. What we try to do is put a situation in place that all teachers can become great teachers. We're focused on kids becoming good learners more than on the content that they learn.”

Stock2Me's latest podcast features Allan Jones, President of Emaginos Inc. During the interview, Jones discussed the company's business model and its vision of leveraging proven best practices to transform public school students from passive listeners into active learners. “We're a company that's dedicated to transforming public education. We have this vision of unleashing America's greatest natural resource – the minds of our children,” Jones said. “A teachable moment occurs when the student wants to learn what the teacher wants to teach. Good teachers can recognize those and take advantage of them; great teachers can create them. What we try to do is put a situation in place that all teachers can become great teachers. We're focused on kids becoming good learners more than on the content that they learn.”

Stock2Me's latest podcast features Paul Duffy, President of Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF). During the interview, Duffy explains how the company's technology uses your smartphone to “augment” your view by superimposing a hologram into your physical location. “What makes us different is that we put augmented reality into everything that we do. AR is the ability to take photorealistic objects – it could be people, products or places – and superimpose them using your smartphone,” Duffy said. “So, as you view your phone over a location you can conjure up a hologram and literally augment the reality of that space. If you want to view a vacuum cleaner, you could literally press a button on our website, and it will conjure up through your browser that particular vacuum as a hologram. You can pinch it, zoom it, rotate it, put it in your closet and take a selfie to send to your partner and say, ‘That's the one we want to buy.' AR is very useful in converting online shoppers into buyers.”

Stock2Me's latest podcast features Paul Duffy, President of Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF). During the interview, Duffy explains how the company's technology uses your smartphone to “augment” your view by superimposing a hologram into your physical location. “What makes us different is that we put augmented reality into everything that we do. AR is the ability to take photorealistic objects – it could be people, products or places – and superimpose them using your smartphone,” Duffy said. “So, as you view your phone over a location you can conjure up a hologram and literally augment the reality of that space. If you want to view a vacuum cleaner, you could literally press a button on our website, and it will conjure up through your browser that particular vacuum as a hologram. You can pinch it, zoom it, rotate it, put it in your closet and take a selfie to send to your partner and say, ‘That's the one we want to buy.' AR is very useful in converting online shoppers into buyers.”

Stock2Me's latest podcast features Staci Wallace, leading expert in the fields of business psychology and process strategy. Wallace helps business owners, leaders and entrepreneurs learn essential hacks to build a life and a business they love. For over 30 years in corporate America, she has been effectively shifting mindsets into greater outcomes as an engaging speaker, thought leader, business executive and author of eight books, including her latest, Fueled by Fire, now available on Amazon. She is also host of the Comeback Small Business Radio Show and holds a black belt in mixed martial arts.

Stock2Me's latest podcast features Staci Wallace, leading expert in the fields of business psychology and process strategy. Wallace helps business owners, leaders and entrepreneurs learn essential hacks to build a life and a business they love. For over 30 years in corporate America, she has been effectively shifting mindsets into greater outcomes as an engaging speaker, thought leader, business executive and author of eight books, including her latest, Fueled by Fire, now available on Amazon. She is also host of the Comeback Small Business Radio Show and holds a black belt in mixed martial arts.

Stock2Me's latest podcast features Lomit Patel, expert in AI and early-stage business growth. Patel is Vice President of Growth at IMVU. He previously managed growth at startups including Roku; TrustedID, which was acquired by Equifax; Texture, which was acquired by Apple; and EarthLink. Patel is a public speaker, author and advisor, and he is recognized as a Mobile Hero by Liftoff. His new bestselling book “Lean AI: How Innovative Startups Use Artificial Intelligence to Grow” is part of Eric Ries' “The Lean Startup” series, now available on Amazon.

Stock2Me's latest podcast features Lomit Patel, expert in AI and early-stage business growth. Patel is Vice President of Growth at IMVU. He previously managed growth at startups including Roku; TrustedID, which was acquired by Equifax; Texture, which was acquired by Apple; and EarthLink. Patel is a public speaker, author and advisor, and he is recognized as a Mobile Hero by Liftoff. His new bestselling book “Lean AI: How Innovative Startups Use Artificial Intelligence to Grow” is part of Eric Ries' “The Lean Startup” series, now available on Amazon.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me's latest podcast features Ian Rosen, fintech and financial media expert. Rosen is former CEO of StockTwits.com, co-founder of Even Financial and former general manager of MarketWatch. Throughout the interview, Rosen discussed business model changes that media companies must make in order to ensure their success going forward. 

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me's latest podcast features Ian Rosen, fintech and financial media expert. Rosen is former CEO of StockTwits.com, co-founder of Even Financial and former general manager of MarketWatch. Throughout the interview, Rosen discussed business model changes that media companies must make in order to ensure their success going forward. 

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me's latest podcast features James Sapirstein, President & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.

The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me's latest podcast features James Sapirstein, President & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.

Stock2Me's latest podcast features John Truman Wolfe, number one best-selling and international award-winning author of The Coming Financial Crisis: A Look Behind the Wizard's Curtain and The 99 Strongest Banks in America. Wolfe is also the editor and publisher of Strategic Financial Intelligence, a monthly newsletter dealing with investing, politics and the economy.

Stock2Me's latest podcast features John Truman Wolfe, number one best-selling and international award-winning author of The Coming Financial Crisis: A Look Behind the Wizard's Curtain and The 99 Strongest Banks in America. Wolfe is also the editor and publisher of Strategic Financial Intelligence, a monthly newsletter dealing with investing, politics and the economy.

Stock2Me's latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN). “Throughout the many years I've been in the [biopharma] space, I really haven't been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we're working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.” VistaGen's lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that's currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.

Stock2Me's latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN). “Throughout the many years I've been in the [biopharma] space, I really haven't been satisfied with the treatment alternatives that have been available to people all around the world who are suffering from mental illness, especially anxiety and depression,” Singh stated during the interview. “VistaGen provides, I think, an opportunity for tremendous excitement, given what we're working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.” VistaGen's lead drug candidate, PH94B, is a first-in-class neuroactive nasal spray that's currently being developed as an acute treatment for anxiety in adults with Social Anxiety Disorder (SAD). Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA), positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with SAD, if planned Phase 3 studies are successful.

Stock2Me's latest podcast features Chris Lahiji, president of LD Micro, and Christopher Miglino, CEO and founder of SRAX Inc. (NASDAQ: SRAX). The two executives joined the show to discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced the closing of the acquisition on September 16, 2020, noting that LD Micro will operate as a wholly owned subsidiary of SRAX and will continue to employ Lahiji, its founder, as its president.

Stock2Me's latest podcast features Chris Lahiji, president of LD Micro, and Christopher Miglino, CEO and founder of SRAX Inc. (NASDAQ: SRAX). The two executives joined the show to discuss the recent acquisition of LD Micro, a leading data and event company serving the small and micro-cap space, by SRAX, a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform, Sequire. SRAX announced the closing of the acquisition on September 16, 2020, noting that LD Micro will operate as a wholly owned subsidiary of SRAX and will continue to employ Lahiji, its founder, as its president.

The Stock2Me Podcast's latest episode features Oren Klaff, a recognized world leading expert on sales, negotiation and raising capital. Oren has extensively studied how humans respond to each other in high-stakes business situations and pioneered the application of neuroscience into raising capital and capital markets programs. His first book, Pitch Anything, has become compulsory reading on Wall Street as well as throughout Silicon Valley and the Fortune 500. More than 1,000,000 copies of Pitch Anything are in print worldwide He also has written for Harvard Business Review, Inc., Advertising Age, Entrepreneur and has been featured in hundreds of periodicals, podcasts, and blogs. Oren is a member of Geyser Holding's investment committee and is Director of Capital Markets at Intersection Capital where he has supervised the placement of over $500 million of investor capital from high net-worth individuals and financial institutions.

The Stock2Me Podcast's latest episode features Oren Klaff, a recognized world leading expert on sales, negotiation and raising capital. Oren has extensively studied how humans respond to each other in high-stakes business situations and pioneered the application of neuroscience into raising capital and capital markets programs. His first book, Pitch Anything, has become compulsory reading on Wall Street as well as throughout Silicon Valley and the Fortune 500. More than 1,000,000 copies of Pitch Anything are in print worldwide He also has written for Harvard Business Review, Inc., Advertising Age, Entrepreneur and has been featured in hundreds of periodicals, podcasts, and blogs. Oren is a member of Geyser Holding's investment committee and is Director of Capital Markets at Intersection Capital where he has supervised the placement of over $500 million of investor capital from high net-worth individuals and financial institutions.

Stock2Me's latest podcast features Brant Pinvidic, an award-winning film director, veteran television producer, C-level sales and presentations coach, Forbes columnist and author of The 3-Minute Rule. Brant Pinvidic leverages the life, business and storytelling lessons developed during his Hollywood career and uses them to uniquely bridge the entertainment industry and the business community. Over the course of 15 years as a television and film producer, Pinvidic created, developed, sold and produced more than 300 television projects across nearly every network, including smash hits like The Biggest Loser, Bar Rescue, Master Chef and Extreme Makeover: Weight Loss Edition.

Stock2Me's latest podcast features Brant Pinvidic, an award-winning film director, veteran television producer, C-level sales and presentations coach, Forbes columnist and author of The 3-Minute Rule. Brant Pinvidic leverages the life, business and storytelling lessons developed during his Hollywood career and uses them to uniquely bridge the entertainment industry and the business community. Over the course of 15 years as a television and film producer, Pinvidic created, developed, sold and produced more than 300 television projects across nearly every network, including smash hits like The Biggest Loser, Bar Rescue, Master Chef and Extreme Makeover: Weight Loss Edition.

Stock2Me's inaugural podcast features William Santana Li, Chairman and CEO of Knightscope. Li is one of the most significant and disruptive influences within America's $500 billion security industry. Knightscope designs and builds Autonomous Security Robots (ASRs), which provide 24/7/365 security in a variety of different locations. Currently employed by a diverse range of customers, including pharmaceutical giant Merck, electronics conglomerate Samsung, movie theater operator Century Theatres, Florida State University and the Texas Children's Hospital, Knightscope's robots have consistently proven themselves with over one million operational hours in the field. These bots have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs; in one case, the machines even prevented the breakout of a major fire. With the goal of making the United States the safest country in the world, Knightscope is currently in the process of raising up to $50 million in growth capital ahead of a planned public listing on the Nasdaq exchange. Join InvestorBrandNetwork's Stuart Smith and Knightscope's William Li in exploring how Knightscope is working to make America safer, one autonomous robot at a time. Risk Factor Knightscope Inc. is currently raising capital through StartEngine Primary LLC.  This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT.  WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE.  THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

Stock2Me's inaugural podcast features William Santana Li, Chairman and CEO of Knightscope. Li is one of the most significant and disruptive influences within America's $500 billion security industry. Knightscope designs and builds Autonomous Security Robots (ASRs), which provide 24/7/365 security in a variety of different locations. Currently employed by a diverse range of customers, including pharmaceutical giant Merck, electronics conglomerate Samsung, movie theater operator Century Theatres, Florida State University and the Texas Children's Hospital, Knightscope's robots have consistently proven themselves with over one million operational hours in the field. These bots have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs; in one case, the machines even prevented the breakout of a major fire. With the goal of making the United States the safest country in the world, Knightscope is currently in the process of raising up to $50 million in growth capital ahead of a planned public listing on the Nasdaq exchange. Join InvestorBrandNetwork's Stuart Smith and Knightscope's William Li in exploring how Knightscope is working to make America safer, one autonomous robot at a time. Risk Factor Knightscope Inc. is currently raising capital through StartEngine Primary LLC.  This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT.  WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE.  THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.